RecruitingChronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.
Sponsor: OHSU Knight Cancer Institute
You may qualify if…
- ✓ \* Willingness to provide written informed consent before any study-specific procedures or activities are performed
- ✓ Age ≥ 18 years of age, at the time of consent
- ✓ Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed
- ✓ History of prior vaccination against common VPD
- ✓ Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days
- ✓ Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus
You may not qualify if…
- ✕ \* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints
- ✕ Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable
Where it's recruiting
Oregon
Portland
Source: ClinicalTrials.gov · NCT06784167 · last updated 2025-09-15